- Home
- EWTX vs SLNO Comparison
EWTX vs SLNO Comparison
Compare EWTX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- SLNO
- Stock Information
- Founded
- EWTX 2017
- SLNO 1999
- Country
- EWTX United States
- SLNO United States
- Employees
- EWTX N/A
- SLNO N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- EWTX Health Care
- SLNO Health Care
- Exchange
- EWTX Nasdaq
- SLNO Nasdaq
- Market Cap
- EWTX 2.3B
- SLNO 2.3B
- IPO Year
- EWTX 2021
- SLNO 2014
- Fundamental
- Price
- EWTX $20.13
- SLNO $68.26
- Analyst Decision
- EWTX Buy
- SLNO Strong Buy
- Analyst Count
- EWTX 8
- SLNO 8
- Target Price
- EWTX $45.38
- SLNO $95.75
- AVG Volume (30 Days)
- EWTX 1.5M
- SLNO 2.0M
- Earning Date
- EWTX 03-03-2025
- SLNO 05-08-2025
- Dividend Yield
- EWTX N/A
- SLNO N/A
- EPS Growth
- EWTX N/A
- SLNO N/A
- EPS
- EWTX N/A
- SLNO N/A
- Revenue
- EWTX N/A
- SLNO N/A
- Revenue This Year
- EWTX N/A
- SLNO N/A
- Revenue Next Year
- EWTX N/A
- SLNO N/A
- P/E Ratio
- EWTX N/A
- SLNO N/A
- Revenue Growth
- EWTX N/A
- SLNO N/A
- 52 Week Low
- EWTX $14.90
- SLNO $36.61
- 52 Week High
- EWTX $38.12
- SLNO $73.97
- Technical
- Relative Strength Index (RSI)
- EWTX 28.86
- SLNO 74.69
- Support Level
- EWTX $21.58
- SLNO $48.29
- Resistance Level
- EWTX $25.36
- SLNO $73.97
- Average True Range (ATR)
- EWTX 1.99
- SLNO 3.37
- MACD
- EWTX -0.38
- SLNO 2.59
- Stochastic Oscillator
- EWTX 2.67
- SLNO 79.51
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.